Vasoactive Peptide Pharmacology

Correct Answer

C — Neurokinin-1 receptor

Rationale

Aprepitant is classified as a neurokinin-1 receptor antagonist. The neurokinin-1 receptor is the primary receptor for substance P, an 11-amino-acid neuropeptide that mediates the delayed phase of chemotherapy-induced nausea and vomiting. By blocking neurokinin-1 receptors in the brainstem — specifically in the area postrema and nucleus tractus solitarius — aprepitant prevents substance P from activating the central vomiting pathway. Serotonin type 3 receptor antagonism is the mechanism of ondansetron and granisetron, which address the acute phase of chemotherapy-induced nausea. Dopamine D2 and histamine H1 receptor blockade are mechanisms of older antiemetics not in this class.

Correct Answer

A — A water-soluble phosphate prodrug of aprepitant that is administered intravenously and converted to aprepitant after administration

Rationale

Fosaprepitant is classified as a water-soluble phosphate ester prodrug of aprepitant. After intravenous administration, it is rapidly converted to aprepitant by plasma phosphatases. This prodrug formulation allows a single intravenous dose on day 1 of chemotherapy to replace the three-day oral aprepitant course in patients who cannot take oral medications. Fosaprepitant and aprepitant therefore share the same pharmacological target — the neurokinin-1 receptor — and the same mechanism, but differ in their formulation, route, and dosing schedule. Fosaprepitant is not a serotonin type 3 receptor antagonist and is not a corticosteroid.

Correct Answer

B — Recombinant human brain natriuretic peptide

Rationale

Nesiritide is classified as a recombinant form of human brain natriuretic peptide. It is administered intravenously for acute decompensated heart failure, where it activates natriuretic peptide receptors to produce venous and arterial vasodilation, natriuresis, and suppression of the renin-angiotensin-aldosterone system. The synthetic vasopressin analog selective for the V2 receptor describes desmopressin. The neprilysin inhibitor used with an angiotensin receptor blocker describes sacubitril in sacubitril-valsartan. Nesiritide is a brain natriuretic peptide analog, not an atrial natriuretic peptide preparation.

Correct Answer

D — Serotonin type 3 receptor

Rationale

Ondansetron is classified as a serotonin type 3 receptor antagonist — a member of the drug class also including granisetron and palonosetron. Serotonin type 3 receptor antagonists block serotonin-mediated emetic signaling in the area postrema and gut, controlling the acute phase of chemotherapy-induced nausea and vomiting that occurs in the first 24 hours after chemotherapy. Neurokinin-1 receptor antagonism is the class of aprepitant and fosaprepitant, which address the delayed phase. Dopamine D2 antagonism describes older antiemetics such as metoclopramide. Histamine H1 antagonism describes antihistamines used for motion sickness and vestibular nausea.

Correct Answer

C — A moderate cytochrome P450 3A4 inhibitor followed by an inducer — a biphasic interaction profile

Rationale

Aprepitant is classified as having a biphasic cytochrome P450 3A4 interaction profile: it initially inhibits cytochrome P450 3A4 for approximately 3 to 5 days after administration, raising plasma levels of co-administered substrates, and then induces the enzyme over the following week, lowering substrate levels. This biphasic profile is pharmacologically distinctive and clinically consequential: when aprepitant is co-administered with dexamethasone — a cytochrome P450 3A4 substrate routinely included in antiemetic regimens — it raises dexamethasone levels approximately twofold, requiring a reduced dexamethasone dose. It also induces warfarin metabolism in the week following use, requiring international normalized ratio monitoring. Aprepitant is both a substrate and a net mixed inhibitor-inducer of cytochrome P450 3A4, not purely one or the other.

Correct Answer

A — Corticosteroid

Rationale

Dexamethasone is classified as a corticosteroid — specifically a synthetic glucocorticoid. In the context of chemotherapy-induced nausea and vomiting, it serves as the third component of the standard three-drug antiemetic regimen alongside a serotonin type 3 receptor antagonist and a neurokinin-1 receptor antagonist. Its antiemetic mechanism is not fully characterized but involves broad anti-inflammatory and anti-nausea effects across both the acute and delayed phases of chemotherapy-induced nausea and vomiting. Its classification as a corticosteroid also underlies the clinically important drug interaction with aprepitant: because dexamethasone is a cytochrome P450 3A4 substrate and aprepitant is a moderate cytochrome P450 3A4 inhibitor, co-administration raises dexamethasone plasma levels approximately twofold, requiring dose reduction.

Correct Answer

B — The acute phase (0 to 24 hours) is driven by serotonin at serotonin type 3 receptors; the delayed phase (24 to 120 hours) is driven predominantly by substance P at neurokinin-1 receptors in the area postrema and nucleus tractus solitarius, making neurokinin-1 antagonism essential for delayed control

Rationale

Chemotherapy-induced nausea and vomiting has two mechanistically distinct phases driven by different neurotransmitter systems. The acute phase, occurring 0 to 24 hours after chemotherapy, is primarily driven by serotonin released from enterochromaffin cells in the gastrointestinal mucosa acting at serotonin type 3 receptors in the area postrema and vagal afferents. Serotonin type 3 antagonists such as ondansetron are effective for this phase. The delayed phase, beginning approximately 24 hours after chemotherapy and peaking at 48 to 72 hours, is driven predominantly by substance P acting at neurokinin-1 receptors in the area postrema and nucleus tractus solitarius. Because the emetic mediator shifts from serotonin to substance P, serotonin type 3 antagonists alone are insufficient for delayed-phase control, and neurokinin-1 receptor antagonism with aprepitant or fosaprepitant is required.

Correct Answer

D — Aprepitant initially inhibits cytochrome P450 3A4, slowing dexamethasone metabolism and raising dexamethasone plasma levels approximately twofold, necessitating a reduced dexamethasone dose to avoid corticosteroid excess

Rationale

Dexamethasone is a cytochrome P450 3A4 substrate. Aprepitant is a moderate cytochrome P450 3A4 inhibitor during the first 3 to 5 days of administration, slowing dexamethasone hepatic metabolism and raising its plasma levels approximately twofold. Standard antiemetic regimens that include aprepitant therefore prescribe a reduced dexamethasone dose to prevent corticosteroid excess — including adverse effects such as hyperglycemia, insomnia, and mood disturbance. Aprepitant subsequently becomes a cytochrome P450 3A4 inducer over the following week, but this induction phase occurs after the acute antiemetic window and is most relevant to warfarin metabolism rather than the antiemetic regimen itself. Aprepitant does not block glucocorticoid receptors and does not displace dexamethasone from plasma proteins.

Correct Answer

A — Nesiritide activates natriuretic peptide receptors on vascular smooth muscle and renal tubular cells, producing venous and arterial vasodilation, natriuresis, and suppression of the renin-angiotensin-aldosterone system

Rationale

Nesiritide is a recombinant form of human brain natriuretic peptide that acts as an exogenous natriuretic peptide receptor agonist. By activating natriuretic peptide receptors — which signal through cyclic guanosine monophosphate — it produces three simultaneous beneficial effects in acute decompensated heart failure: venous and arterial vasodilation (reducing both preload and afterload), natriuresis and diuresis (reducing volume overload through renal tubular mechanisms), and suppression of the renin-angiotensin-aldosterone system and sympathetic nervous system activation. These effects are mechanistically complementary to intravenous diuretics. Neprilysin inhibition describes sacubitril's mechanism — the approach taken in sacubitril-valsartan to preserve endogenous natriuretic peptides rather than supplying them exogenously. Nesiritide does not block vasopressin receptors or stimulate adrenergic receptors.

Correct Answer

C — Nesiritide produced modest dyspnea improvement that did not reach statistical significance, with no reduction in mortality or rehospitalization; it is an adjunct to diuretics, not a replacement

Rationale

The ASCEND heart failure trial compared nesiritide added to standard care versus standard care alone in over 7,000 patients with acute decompensated heart failure. Nesiritide produced a modest improvement in patient-reported dyspnea at 6 and 24 hours — the primary endpoint — but this improvement did not reach statistical significance. There was no reduction in 30-day mortality or rehospitalization. Nesiritide also did not increase renal dysfunction compared to placebo, resolving an earlier concern from smaller studies, but neither did it improve renal outcomes. The clinical implication is that nesiritide is not a replacement for intravenous loop diuretics, which remain first-line treatment for acute decompensated heart failure with volume overload. Nesiritide may have a limited adjunct role in selected patients with predominantly vasodilatory hemodynamics or diuretic resistance. This contrasts with sacubitril-valsartan, which targets the same natriuretic peptide system through neprilysin inhibition and has demonstrated mortality benefit in chronic heart failure.

Correct Answer

B — Obesity suppresses brain natriuretic peptide secretion and clearance through mechanisms not fully understood, causing levels to remain in the normal range even when cardiac filling pressures are elevated

Rationale

Obesity produces a clinically significant reduction in plasma brain natriuretic peptide levels through incompletely characterized mechanisms that affect both secretion and clearance of the peptide. The net result is that obese patients with heart failure and elevated ventricular filling pressures may have brain natriuretic peptide values that fall within the normal diagnostic range, creating the risk of falsely reassuring results and underdiagnosis. In this patient, the low brain natriuretic peptide level does not reliably exclude heart failure as the cause of her symptoms given her obesity and her known heart failure history. Adipose tissue does not produce brain natriuretic peptide — the peptide is released by ventricular cardiomyocytes in response to wall stress. Neprilysin activity is not selectively increased in obesity. The assay does not cross-react with adipokines in a way that mechanistically lowers brain natriuretic peptide values.

Correct Answer

D — NT-proBNP relies on renal clearance, and as glomerular filtration rate declines the peptide accumulates in plasma independently of ventricular wall stress, raising values above the standard diagnostic threshold even without worsening heart failure

Rationale

NT-proBNP is cleared primarily by the kidney through glomerular filtration. As glomerular filtration rate declines in chronic kidney disease, NT-proBNP accumulates in plasma even in the absence of worsening ventricular wall stress. This renal accumulation effect is particularly pronounced for NT-proBNP, which relies more heavily on renal clearance than brain natriuretic peptide does. The standard diagnostic threshold of 300 pg/mL for acute heart failure in the emergency setting was established in populations with normal or near-normal renal function. In patients with chronic kidney disease, age-stratified and renal-function-adjusted thresholds should be applied, or additional clinical information should be used alongside the biomarker value. NT-proBNP is produced by ventricular cardiomyocytes, not by the kidney. NT-proBNP is not a neprilysin substrate — it is the inactive cleavage fragment that is not degraded by neprilysin. Uremia does not produce immunoassay cross-reactivity with NT-proBNP.

Correct Answer

A — Aprepitant induces cytochrome P450 2C9 and 3A4 in the week following administration, accelerating warfarin metabolism and reducing plasma warfarin levels and anticoagulant effect

Rationale

Aprepitant has a biphasic cytochrome P450 interaction profile. During the first 3 to 5 days of administration it inhibits cytochrome P450 3A4, raising levels of co-administered substrates such as dexamethasone. In the week following the antiemetic course, aprepitant induces cytochrome P450 2C9 and 3A4. Warfarin is metabolized predominantly by cytochrome P450 2C9; induction of this enzyme accelerates warfarin hepatic metabolism, lowers plasma warfarin levels, and reduces the international normalized ratio and anticoagulant effect. Patients on warfarin receiving aprepitant require international normalized ratio monitoring in the week following the antiemetic course to detect and correct this reduction in anticoagulation. The mechanism is enzyme induction, not vitamin K antagonism, cytochrome P450 inhibition, or protein binding displacement.

Correct Answer

C — The three agents target complementary emetic pathways: the serotonin type 3 antagonist controls the acute serotonin-mediated phase, the neurokinin-1 antagonist controls the delayed substance P-mediated phase, and dexamethasone provides broad anti-nausea coverage across both phases

Rationale

The three-drug antiemetic regimen is designed around the mechanistic distinction between the acute and delayed phases of chemotherapy-induced nausea and vomiting. The serotonin type 3 receptor antagonist (ondansetron, granisetron, or palonosetron) blocks serotonin-mediated emetic signaling in the area postrema and gut, controlling the acute phase from 0 to 24 hours. The neurokinin-1 receptor antagonist (aprepitant or fosaprepitant) blocks substance P-mediated activation of the vomiting center, controlling the delayed phase from 24 to 120 hours that serotonin type 3 antagonists cannot adequately address. Dexamethasone, whose antiemetic mechanism involves broad anti-inflammatory effects reducing prostaglandin-mediated nausea, provides coverage across both phases. Because each drug targets a different neurotransmitter pathway, the combination produces additive efficacy without pharmacodynamic redundancy. Dexamethasone does not inhibit cytochrome P450 enzymes or extend half-lives of the other agents — it is the aprepitant component that raises dexamethasone levels through cytochrome P450 3A4 inhibition, not the reverse.

Correct Answer

B — Aprepitant inhibits cytochrome P450 3A4, raising dexamethasone plasma levels approximately twofold above the expected concentration and producing corticosteroid excess effects including hyperglycemia and insomnia

Rationale

Aprepitant is a moderate cytochrome P450 3A4 inhibitor during the antiemetic course. Dexamethasone is a cytochrome P450 3A4 substrate. When the standard dexamethasone dose designed for use without aprepitant is given alongside aprepitant, the inhibition of cytochrome P450 3A4 slows dexamethasone metabolism and raises plasma dexamethasone levels approximately twofold. The patient is effectively receiving double the intended corticosteroid exposure, producing typical corticosteroid excess effects: hyperglycemia from glucocorticoid-induced insulin resistance, insomnia and restlessness from glucocorticoid central nervous system effects, and potentially other signs of hypercortisolism. Standard antiemetic protocols that include aprepitant prescribe a reduced dexamethasone dose — typically half the standard dose — to account for this pharmacokinetic interaction. The interaction direction is aprepitant raising dexamethasone levels, not the reverse.

Correct Answer

D — Obesity suppresses brain natriuretic peptide secretion and clearance, causing levels to remain in the normal range even when cardiac filling pressures are elevated; a brain natriuretic peptide of 85 pg/mL does not exclude heart failure in an obese patient

Rationale

Obesity is a recognized cause of falsely low brain natriuretic peptide levels. Through mechanisms not fully understood, obesity suppresses both the secretion of brain natriuretic peptide from ventricular cardiomyocytes and its clearance from the circulation, resulting in lower circulating levels than would be expected for a given degree of ventricular wall stress. In an obese patient, a brain natriuretic peptide value of 85 pg/mL — below the standard diagnostic threshold of 100 pg/mL for acute heart failure — may still represent elevated filling pressures that would produce a much higher value in a non-obese patient with the same hemodynamic state. The standard diagnostic thresholds for brain natriuretic peptide were derived in populations that included relatively few severely obese patients and may not be directly applicable in this setting. Further cardiac evaluation — including echocardiography — is warranted in this patient given her symptoms and obesity-related biomarker limitation.

Correct Answer

A — The ASCEND heart failure trial showed nesiritide did not reduce 30-day mortality or rehospitalization compared to standard care; nesiritide is an adjunct to loop diuretics in selected patients, not a replacement for them

Rationale

The ASCEND heart failure trial enrolled over 7,000 patients with acute decompensated heart failure and compared nesiritide added to standard care versus standard care alone. Nesiritide produced a modest improvement in patient-reported dyspnea that did not reach statistical significance on the primary endpoint. Of particular note for this clinical scenario, there was no reduction in 30-day mortality or rehospitalization. Nesiritide also did not worsen renal function compared to placebo, resolving an earlier concern, but neither did it improve renal outcomes. Intravenous loop diuretics remain first-line therapy for acute decompensated heart failure with volume overload because they reliably reduce filling pressures and relieve symptoms. Nesiritide may have a limited adjunct role in patients with predominantly vasodilatory hemodynamics or diuretic resistance, but it cannot replace diuretics and does not provide the mortality or readmission benefit the cardiologist expects. The ASCEND heart failure trial — not a trial called PARADIGM — is the relevant evidence for nesiritide; PARADIGM heart failure evaluated sacubitril-valsartan in chronic heart failure management.

Correct Answer

C — Delayed nausea is driven by substance P acting at neurokinin-1 receptors, not by serotonin; ondansetron does not address this phase and a neurokinin-1 receptor antagonist such as aprepitant should be added to the regimen

Rationale

This patient's pattern — minimal nausea in the first 24 hours but severe nausea at 48 to 72 hours — is the classic presentation of the delayed phase of chemotherapy-induced nausea and vomiting. The acute phase (0 to 24 hours) is driven by serotonin released from gastrointestinal enterochromaffin cells, and ondansetron's serotonin type 3 receptor blockade was effective for this phase. The delayed phase (24 to 120 hours, peaking at 48 to 72 hours) is driven predominantly by substance P acting at neurokinin-1 receptors in the area postrema and nucleus tractus solitarius. Ondansetron has no activity at neurokinin-1 receptors and cannot control this phase. The appropriate addition to the next cycle's regimen is a neurokinin-1 receptor antagonist — aprepitant orally on days 1 through 3, or fosaprepitant as a single intravenous dose on day 1 — in combination with continued ondansetron and dexamethasone. This three-drug regimen addresses all three major emetic pathways.